NeuDirection Limited
Innovative Drugs
in CNS disease
Advancing Treatment for Neurological Challenges
Our Mission
Targeting unexplored G protein-coupled receptors (GPCRs) in the brain with novel small-molecule, neuropeptide mimetics for the treatment of rare and neglected Central Nervous System (CNS) diseases……
New Drug Pipelines
Explore our innovative drug pipelines
Amblyopia
Neu-001, a novel small molecule agonist targeting a groundbreaking GPCR in the visual cortex, offers new hope for amblyopia patients.
Tinnitus
Neu-002, an innovative small molecule agonist targeting a key GPCR in the auditory cortex, presents a novel approach to treating tinnitus.
Memory Deficit Syndromes
Neu-003, a first-in-class oral agonist targeting a pivotal neocortical GPCR, offering a promising new therapeutic avenue for patients with Memory Deficit Syndromes.